Effect of tissue penetration on AmBisome efficacy

Current Opinion in Investigational Drugs

Volumn 4, Issue 2, 2003, Pages 179-185

  Adler Moore, Jill ^a   Proffitt, Richard T ^b  

^a CALIFORNIA STATE POLYTECHNIC UNIVERSITY   (United States)

^b NONE   (United States)

Author keywords

AmBisome; Aspergillosis; Candida albicans; Fusariosis; Leishmaniasis; Reticuloendothelial system

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; FLUCONAZOLE;

ANIMAL MODEL; ANTIFUNGAL ACTIVITY; BRAIN INFECTION; DISEASE MODEL; DOSE CALCULATION; DOSE RESPONSE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG PENETRATION; DRUG SAFETY; DRUG TARGETING; DRUG TOXICITY; HEPATITIS; KIDNEY INFECTION; LUNG INFECTION; MYCOSIS; NEPHROTOXICITY; NONHUMAN; RETICULOENDOTHELIAL SYSTEM; REVIEW; SKIN INFECTION; SPLEEN DISEASE;

AMPHOTERICIN B; ANIMALS; ANTIBIOTICS, ANTIFUNGAL; BRAIN DISEASES; DERMATOMYCOSES; HUMANS; LIVER DISEASES; LUNG DISEASES, FUNGAL; MYCOSES; SPLENIC DISEASES;

EID: 0037301430     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Sculier JP, Coune A, Meunier F, Brassinne C, Laduron C, Hollaert C, Collette N, Heymans C, Klastersky J: Pilot study of amphotericin B entrapped in sonicated liposomes in cancer patients with fungal infections. Eur J Cancer Clin Oncol (1988) 24(3):527-538.
2. Lopez-Berestein G, Mehta R, Hopfer RL, Mills K, Kasi L, Mehta K, Fainstein V, Luna M, Hersh EM, Juliano R: Treatment and prophylaxis of disseminated infection due to Candida albicans in mice with liposome-encapsulated amphotericin B. J Infect Dis (1983) 147(5):939-945.
3. Graybill JR, Craven PC, Taylor RL, Williams DM, Magee WE: Treatment of murine cryptococcosis with liposome-associated amphotericin B. J Infect Dis (1982) 145(5):748-752.
4. Ringden O: Ten years' experience with liposomal amphotericin B in transplant recipients at Huddinge University Hospital. J Antimicrob Chemother (2002) 49(Suppl 1):51-55.
5. Goodman JS, Koenig MG: Amphotericin B - Specifics of administration. Mod Treatment (1970) 7(3):581-595.
6. Adler-Moore J, Proffitt RT: AmBisome: Liposomal formulation, structure, mechanism of action and pre-clinical experience. J Antimicrob Chemother (2002) 49(Suppl 1):21-30. This paper describes essential preclinical information about AmBisome.
7. Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, Bodensteiner D, Pappas P, Seibel N, Greenberg RN, Dummer S, Schuster M et al: Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med (1999) 340(10):764-771.
8. Prentice HG, Hann IM, Hebrecht R, Aoun M, Kvaloy S, Catovsky D, Pinkerton CR, Schey SA, Jacobs F, Oakhill A, Stevens RF et al: A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol (1997) 98(3):711-718.
9. Wingard JR, White MH, Anaissie E, Raffalli J, Goodman J, Arrieta A: A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clin Infect Dis (2000) 31(5):1155-1163.
10. Albert MM, Stahl-Carroll L, Luther MF, Graybill JR: Comparison of liposomal amphotericin B to amphotericin B for treatment of murine cryptococcal meningitis. J Mycol Med (1995) 5:1-6. This paper describes the improved efficacy of using high-dose AmBisome for brain infections and the sustained bioactivity of AmBisome in the brain.
11. Clemons KV, Stevens DA: Comparison of a liposomal amphotericin B formulation (AmBisome) and deoxycholate amphotericin B (Fungizone) for the treatment of murine paracoccidioidomycosis. J Med Vet Mycol (1993) 31:387-394.
12. Walsh TJ, Goodman JL, Pappas P, Bekersky I, Buell DN, Roden M, Barrett J, Anaissie EJ: Safety, tolerance and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: Maximum tolerated dose study. Antimicrob Agents Chemother (2001) 45(12):3487-3496.
13. White MH, Bowden RA, Sandler ES, Graham ML, Noskin GA, Wingard JR, Goldman M, Van Burik JA, McCabe A, Lin JS, Gurwith M, Miller CB. Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis (1998) 27(2):296-302.
14. Guo LSS, Fielding RM, Lasic DD: Novel antifungal drug delivery: Stable amphotericin B cholesteryl sulfate discs. Internatl J Pharmaceut (1991) 75:45-54.
15. Janoff AS, Boni LT, Popescu MC, Minchey SR, Cullis PR, Madden TD, Taraschi T, Gruner SM, Shyamsunder E, Tate MW, Mendelsohn R, Bonner D: Unusual lipid structures selectively reduce the toxicity of amphotericin B. Proc Natl Acad Sci USA (1988) 85(16):6122-6126.
16. Adler-Moore JP, Proffitt RT: Development, characterization, efficacy and mode of action of AmBisome, a unilamellar formulation of amphotericin B. J Liposome Res (1993) 3(3):429-450.
17. Readio JD, Bittman R. Equilibrium binding of amphotericin B and its methyl ester and borate complex to sterols. Biochim Biophys Acta (1982) 685(2):219-24.
18. Adler-Moore J: AmBisome targeting to fungal infections. Bone Marrow Transplant (1994) 14(Suppl 5):S3-S7. This paper describes the mechanism of action of AmBisome and the sustained bioactivity of AmBisome for clearing a spleen infection.
19. Boswell GW, Bekersky I, Buell D, Hiles R, Walsh TJ: Toxicological profile and pharmacokinetics of a unilamellar liposomal vesicle formulation of amphotericin B in rats. Antimicrob Agents Chemother (1998) 42(2):263-268.
20. Bekersky I, Boswell GW, Hiles R, Fielding RM, Buell D, Walsh TJ: Safety and toxicokinetics of intravenous liposomal amphotericin B (AmBisome) in beagle dogs. Pharm Res (1999) 16(11):1694-1701.
21. Lee JW, Amantea MA, Francis PA, Navarro EE, Bacher J, Pizzo PA, Walsh TJ: Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in rabbits. Antimicrob Agents Chemother (1994) 38(4):713-718.
22. Heinemann V, Bosse D, Jehn U, Kahny B, Wachholz K, Debus A, Scholz P, Kolb HJ, Wilmanss W: Pharmacokinetics of liposomal amphotericin B (AmBisome) in critically ill patients. Antimicrob Agents Chemother (1997) 41(6):1275-1280.
23. Walsh TJ, Yeldandi V, McEvoy M, Gonzalez C, Chanock S, Freifeld A, Seibel NI, Whitcomb PO, Jarosinski P, Boswell G, Bekersky I et al: Safety, tolerance and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients. Antimicrob Agents Chemother (1998) 42(9):2391-2398.
24. Bekersky I, Boswell GW, Hiles R, Fielding RM, Buell D, Walsh TJ: Safety, toxicokinetics and tissue distribution of long-term intravenous liposomal amphotericin B (AmBisome): A 91-day study in rats. Pharm Res (2000) 17(12):1494-1502. This paper provides detailed information about the biodistribution of repeated dosing of AmBisome and sustained drug tissue levels post-treatment.
25. Francis P, Lee JW, Hoffman A, Peter J, Francesconi A, Bacher J, Shelhamer J, Pizzo PA, Walsh TJ: Efficacy of unilamellar liposomal amphotericin B in treatment of pulmonary aspergillosis in persistently granulocytopenic rabbits: The potential role of bronchoalveolar D-mannitol and serum galactomannan as markers of infection. J Infect Dis (1994) 169(2):356-368.
26. Leenders ACAP, De Marie S, Ten Kate MT, Bakker-Woudenberg IA, Verbrugh HA: Liposomal amphotericin B (AmBisome) reduces dissemination of infection as compared with amphotericin B deoxycholate (Fungizone) in a rat model of pulmonary aspergillosis. J Antimicrob Chemother (1996) 38(2):215-225. This paper describes the effectiveness of high-dose AmBisome in preventing fungal dissemination from the lungs to other tissues.
27. Ruijgrok EJ, Vulto AG, Van Etten EW: Efficacy of aerosolized amphotericin B desoxycholate and liposomal amphotericin B in the treatment of invasive pulmonary aspergillosis in severely immunocompromised rats. J Antimicrob Chemother (2001) 48(1):89-95.
28. Clemons KV, Stevens DA: Therapeutic efficacy of a liposomal formulation of amphotericin B (AmBisome) against murine blastomycosis. J Antimicrob Chemother (1993) 32(3):465-472.
29. Clemons KV, Sobel RA, Williams PL, Pappagianis D, Stevens DA: Efficacy of intravenous liposomal amphotericin B (AmBisome) against coccidioidal meningitis in rabbits. Antimicrob Agents Chemother (2002) 46(8):2420-2426. This paper supports the use of high-dose AmBisome for difficult to treat central nervous system infections, such as coccidioidal meningitis.
30. Groll AH, Mickiene D, Petraitis V, Petraitiene R, Roussillon K, Hemmings M, Lyman CA, Walsh TJ: Disposition and efficacy of amphotericin B formulations in a kidney target model of invasive candidiasis. ICAAC (2001) 41:Abs J-1607.
31. Van Etten EW, Van Den Heuvel-De Groot C, Bakker-Woudenberg IA: Efficacies of amphotericin B-desoxycholate (Fungizone), liposomal amphotericin B (AmBisome) and fluconazole in the treatment of systemic candidosis in immunocompetent and leucopenic mice. J Antimicrob Chemother (1993) 32(5):723-739. This paper describes the sustained bioactivity of high-dose AmBisome for the treatment of kidney infections.
32. Van Etten EW, Otte-Lambillion M, Van Vianen W, Ten Kate MT, Bakker-Woudenberg AJ: Biodistribution of liposomal amphotericin B (AmBisome) and amphotericin B-desoxycholate (Fungizone) in uninfected immunocompetent mice and leucopenic mice infected with Candida albicans. J Antimicrob Chemother (1995) 35(4):509-519.
33. Boutati EI, Anaissie EJ: Fusarium, a significant emerging pathogen in patients with hematologic malignancy: Ten years' experience at a cancer center and implications for management. Blood (1997) 90(3):999-1008.
34. Ortoneda M, Capilla J, Pastor FJ, Pujol I, Guarro J: Efficacy of liposomal amphotericin B in treatment of systemic murine fusariosis. Antimicrob Agents Chemother (2002) 46(7):2273-2275. This paper shows the improved efficacy of high-dose AmBisome for difficult to treat infections, such as fusariosis.
35. Berman JD, Hanson WL, Chapman WL, Alving CR, Lopez-Berestein G: Anti-leishmanial activity of liposome-encapsulated amphotericin B in hamsters and monkeys. Antimicrob Agents Chemother (1986) 30(6):847-851.
36. Gangneux JP, Sulahian A, Garin YJ, Farinotti R, Derouin F: Therapy of visceral leishmaniasis due to Leishmania infantum: Experimental assessment of efficacy of AmBisome. Antimicrob Agents Chemother (1996) 40(5):1214-1218. This paper describes the efficacy of high-dose AmBisome for treating a systemic infection which localizes in the RES and non-RES tissues, the sustained bioactivity of AmBisome in the tissues and a correlation between tissue drug concentration and drug efficacy.
37. Gibbs DM, Olson JA, Adler-Moore JP: Clearance of Candida albicans from infected vaginal tissues of immunosuppressed mice following treatment with AmBisome. Am Soc Microbiol (2002) 102:Abs F48.
38. Yardley V, Croft SL: Activity of liposomal amphotericin B against experimental cutaneous leishmaniasis. Antimicrob Agents Chemother (1997) 41(4):752-756. This paper demonstrates that intravenously administered AmBisome can biodistribute to the skin as evidenced by the efficacy of high-dose AmBisome for resolving skin lesions.
39. Panosian CB, Barza M, Szoka F, Wyler DJ: Treatment of experimental cutaneous leishmaniasis with liposome-intercalated amphotericin B. Antimicrob Agents Chemother (1984) 25(5):655-656.
40. Llanos-Cuentas A, Echevarria J, Chang P, Campos J, Cieza D, Lentnek D, Gonzalez M, Robbins JB, Williams R: Randomized trial of amphotericin B complex (ABLC) versus Fungizone in patients with mucocutaneous leishmaniasis. Mem Inst Oswaldo Cruz (1991) 86(Suppl 1):238.
41. Olson JA, Adler-Moore JP, Proffitt RT: Efficacy of AmBisome (AMBI) loading dose regimens for the treatment of systemic candidiasis in immunosuppressed mice. 9th Annual Focus on Fungal Infections, San Diego, CA, USA (1999):Abs 022.
42. Garcia A, Adler-Moore JP, Proffitt RT: Single-dose AmBisome (Liposomal amphotericin B) as prophylaxis for murine systemic candidiasis and histoplasmosis. Antimicrob Agents Chemother (2000) 44(9):2327-2332. This paper describes the efficacy of intravenous AmBisome for prophylaxis and a correlation between the efficacy and tissue drug concentration at the time of fungal challenge.
43. BitMansour A, Brown JM: Prophylactic administration of liposomal amphotericin B is superior to treatment in a murine model of invasive aspergillosis after hematopoietic cell transplantation. J Infect Dis (2002) 186(1):134-137.
44. Allen SD, Sorensen KN, Nejdl MJ, Durrant C, Proffitt RT: Prophylactic efficacy of aerosolized liposomal (AmBisome) and non-liposomal (Fungizone) amphotericin B in murine pulmonary aspergillosis. J Antimicrob Chemother (1994) 34(6):1001-1013. This paper describes the efficacy of aerosolized AmBisome for prophylaxis and the high drug levels in the lungs achieved by the aerosol route of administration.
45. Collette N, Van Der Auwera P, Meunier F, Lambert C, Sculier JP, Coune A: Tissue distribution and bioactivity of amphotericin B administered in liposomes to cancer patients. J Antimicrob Chemother (1991) 27(4):535-548.
46. Christiansen KJ, Bernard EM, Gold JW, Armstrong D: Distribution and activity of amphotericin B in humans. J Infect Dis (1985) 152(5):1037-1043.
47. Olson JA, Adler-Moore JA: Correlation between drug lung concentrations, colony forming units (CFU) and survival following AmBisome (AmBi) or Abelcet (Ablt) treatment of pulmonary aspergillosis in immunosuppressed mice. ICAAC (2001) 41:Abs J-1835.
48. Croft SL, Davidson RN, Thornton EA: Liposomal amphotericin B in the treatment of visceral leishmaniasis. J Antimicrob Chemother (1991) 28(Suppl B):111-118.
49. Proffitt RT, Satorius A, Chiang S-M, Sullivan L, Adler-Moore JP: Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents. J Antimicrob Chemother (1991) 28(Suppl B):49-61.
50. Groll AH, Giri N, Petraitis V, Petraitiene R, Candelario M, Bacher JS, Piscitelli SC, Walsh TJ: Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J Infect Dis (2000) 182(1):274-282. This paper describes the comparative efficacy of different amphotericin B lipid formulations in treating an infection of the central nervous system and the increased penetration of AmBisome into the brain.